Key result
Higher serum PINP linked to ~95% higher 1-year major cardiovascular events risk in newly diagnosed heart failure.
Why the study?
The association of serum Procollagen I N-Terminal Propeptide (PINP) with myocardial fibrosis and its predictive value for major adverse cardiovascular events in newly diagnosed heart failure patients was unclear.
Are higher serum PINP levels associated with myocardial fibrosis and increased risk of MACE in patients with newly diagnosed heart failure with reduced ejection fraction?
Cohort (n=76)
No
Are higher serum PINP levels associated with myocardial fibrosis and increased risk of MACE in patients with newly diagnosed heart failure with reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
In newly diagnosed HFrEF, elevated serum PINP levels correlate with myocardial fibrosis on CMR and predict a higher risk of MACE at one year.
OBJECTIVES: To investigate the association of Procollagen I N-Terminal Propeptide (PINP) with myocardial fibrosis (MF) and its predictive effect on major adverse cardiovascular events (MACEs) in patients with primary diagnosis of heart failure (HF). METHODS: A total of 76 newly diagnosed HF patients with reduced ejection fraction were followed up for one year. Serum PINP levels and extracellular volumes (ECV) quantified by cardiac magnetic resonance(CMR) imaging at baseline were collected. MF was defined when a ECV value was greater than 28.5%. The first MACEs defined as rehospitalization and/or cardiovascular death, were recorded during the visit. RESULTS: The levels of PINP in patients with MF were higher than those in patients without MF (39.90 VS 49.10 ng/ml, P = 0.030). Multivariate logistic regression analysis showed that PINP was an independent risk factor for MF (OR 1.058, 95% CI 1.018 ~ 1.098, P = 0.004). The linear regression model showed a linear correlation between the PINP levels and ECVs (R = 0.280, P = 0.014). Patients with higher PINP levels had a significant increased risk of incident MACE than those with lower PINP levels (HR 1.95, 95%CI 1.03 ~ 3.69, P = 0.033). CONCLUSION: In patients with newly diagnosed HF, serum PINP levels were associated with MF and an increased risk of MACEs during a one-year follow-up.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=76). Serum Procollagen I N-Terminal Propeptide (PINP) levels vs. Lower PINP levels was evaluated on Major adverse cardiovascular events (MACEs), defined as rehospitalization due to worsening HF and/or cardiovascular mortality (HR 1.95, 95% CI 1.03-3.69, p=0.033). In patients with newly diagnosed heart failure, higher serum PINP levels were associated with a increased risk of major adverse cardiovascular events over one year.
Synapse has enriched 10 related papers. Consider them for comparative context: